Amir Soltanianzadeh

CEO of StimCardio in Los Angeles  

Amir is a serial entrepreneur, investor and business leader on a mission to fundamentally change how atrial fibrillation is detected and treated. At 31, he is leading the development of the world’s first wearable that is capable of both identifying atrial fibrillation (AFib) and delivering non-invasive neuromodulation therapy to treat it, all from a device designed for everyday life. 

The clinical case for StimCardio is compelling. AFib affects more than 37 million people globally and is a leading cause of stroke, heart failure, hospitalizations and healthcare cost. Current management options carry real limitations. Antiarrhythmic drugs come with systemic side effects, and catheter ablation is invasive with variable long-term outcomes. A wearable that can close the detect-to-treat loop non-invasively—in real time, in the community setting—would represent a paradigm shift in AFib care. 

Amir’s path to this moment is itself a story worth telling. A Johns Hopkins innovation program graduate, he founded and exited his first startup in his mid-20s, then turned to investing through Solardis Ventures, backing companies across the cardiac care ecosystem before returning to the operator seat as CEO of StimCardio. That arc—builder, exiter, investor builder again—reflects his uncommon combination of entrepreneurial range and sector depth. 

Supported by an experienced medtech board and publicly championed at industry forums including Life Science Innovators, Amir Soltanianzadeh is advancing StimCardio toward clinical validation and regulatory clearance. He is only 31, yet he is not just forecasting the future of cardiac care but also engineering it.